Results 71 to 80 of about 3,494 (189)
Clinical and Translational Science, Volume 18, Issue 6, June 2025.ABSTRACT It is unclear whether Japanese top‐selling drugs have meaningful added therapeutic benefits to justify their high sales. This question is relevant as Japan's healthcare costs are rising consistently, particularly due to increasing drug prices.
Hayase Hakariya +5 more
wiley +1 more source
Paying for "End-of-Life" Drugs in Australia, Germany, and the United Kingdom: Balancing Policy, Pragmatism, and Societal Values [PDF]
, 2012 Analyzes British, Australian, and German health systems' policies on covering expensive end-of-life drugs while maintaining equity and efficiency, such as requiring evidence of comparative clinical and cost-effectiveness.
Andreas Gerber +2 more
core
Journal of Advanced Nursing, Volume 81, Issue 5, Page 2810-2818, May 2025.ABSTRACT Background Scientific research has consistently emphasised the high levels of stress encountered by family caregivers of individuals living with dementia. However, conventional self‐help approaches remain underutilised. The ‘Diversity‐On’ study addresses this issue.
Kübra Annac +9 more
wiley +1 more source
Modelling Volume‐Outcome Relationships in Health Care
Statistics in Medicine, Volume 44, Issue 6, 15 March 2025.ABSTRACT Despite the ongoing strong interest in associations between quality of care and the volume of health care providers, a unified statistical framework for analyzing them is missing, and many studies suffer from poor statistical modelling choices.
Maurilio Gutzeit +3 more
wiley +1 more source
Die Bedeutung des Behandlungsprozesses in Deutschland: Eine Discrete-Choice-Analyse zu Patientenpräferenzen in der komplementären und konventionellen Medizin [PDF]
, 2019 Hintergrund: Die Auswirkungen von gesundheitlichen Interventionen sind häufig komplex. Es wird argumentiert, dass sie mehr umfassen als reine Veränderungen in den klinischen Parametern. Die Aspekte des Behandlungsprozesses, so genannte „benefits beyond
Adam, Daniela
core +1 more source
Health and Quality of Life OutcomesObjectives Estimates of minimally important differences (MID) can assist interpretation of data collected using patient-reported outcomes (PRO), but variability exists in the emphasis placed on MIDs in health technology assessment (HTA) guidelines.
Caroline Shaw +4 more
doaj +1 more source
Therapy preferences of patients with lung and colon cancer: A discrete choice experiment [PDF]
, 2017 Objectives: There is increasing interest in studies that examine patient preferences to measure health-related outcomes. Understanding patients’ preferences can improve the treatment process and is particularly relevant for oncology.
Damm, Kathrin +6 more
core +2 more sources
, 2017 Medizintechnische Innovationen stehen in einem komplexen Spannungsfeld zwischen Machbarkeit, Sicherheit, Wirksamkeit und Wirtschaftlichkeit. Dies verlangt nach geeigneten Steuerungsinstrumenten, die einerseits sicherstellen, dass die Patientensicherheit ...
Merkel, Sebastian, von Bandemer, Stephan
core
How health technology assessment agencies address the issue of unpublished data [PDF]
, 2014 Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG geförderten) Allianz- bzw. Nationallizenz frei zugänglich.This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence
Busse, Reinhard +2 more
core +1 more source
Communicating the risk of MRSA: the role of clinical practice, regulation and other policies in five European countries [PDF]
, 2017 Background: The threat posed by Meticillin-resistant Staphylococcus aureus (MRSA) has taken on an increasingly pan-European dimension. This article aims to provide an overview of the different approaches to the control of MRSA adopted in five European ...
Arino-Blasco, Sergio +6 more
core +1 more source